News | February 05, 2026
AstraZeneca & Daiichi Sankyo gain priority review for Datroway in hard-to-treat breast cancer
The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)
The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)
A final decision on the updated application is expected in the first half of 2026, while intravenous (IV) Saphnelo remains commercially available
The company maintained a competitive ARPOB while steadily improving occupancy, driven by higher patient volumes and efficient capacity utilization
The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy
The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated
The new service delivers end-to-end support, managing every stage of an epigenomics project
Nine-month revenue grew 17.5% to Rs 76,277 lakh, EBITDA climbed to Rs 15,981 lakh, and net profit reached Rs 8,200 lakh
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
Subscribe To Our Newsletter & Stay Updated
